Functional effects of the MLH1-93G>A polymorphism on MLH1/EPM2AIP1 promoter activity

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 809-815

  Perera, Sheron ^a   Mrkonjic, Miralem ^a   Rawson, James B ^a   Bapat, Bharati ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Colorectal cancer; Endometrial cancer; EPM2AIP1; Functional polymorphism; Mismatch repair; MLH1

Indexed keywords

LUCIFERASE; PROTEIN MLH1;

ALLELE; ANIMAL CELL; ARTICLE; CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; EPM2AIPI GENE; GEL MOBILITY SHIFT ASSAY; GENE; GENETIC TRANSCRIPTION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA; CARRIER PROTEINS; CELLS, CULTURED; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; MICROSATELLITE INSTABILITY; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 79551593446     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1129     Document Type: Article

References (24)

1. Schofield MJ and Hsieh P: DNA mismatch repair: molecular mechanisms and biological function. Annu Rev Microbiol 57: 579-608, 2003.
2. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, et al: Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816, 1993.
3. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, et al: Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54: 1645-1648, 1994.
4. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, Young J, Jenkins MA, Hopper JL, Baron JA, Buchanan D, Casey G, Levine AJ, Le Marchand L, Gallinger S, Bapat B, Potter JD, Newcomb PA, Haile RW and Laird PW: Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17: 3208-3215, 2008.
5. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY and Mutch DG: Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 100: 5908-5913, 2003.
6. Lu KH and Broaddus RR: Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer 4: 249-254, 2005.
7. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, Egger G, Gal-Yam EN and Jones PA: Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12: 432-444, 2007.
8. Hitchins MP, Lin VA, Buckle A, Cheong K, Halani N, Ku S, Kwok CT, Packham D, Suter CM, Meagher A, Stirzaker C, Clark S, Hawkins NJ and Ward RL: Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Res 67: 9107-9116, 2007.
9. Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, Daftary D, Dicks E, Younghusband BH, Parfrey PS, Gallinger SS, McLaughlin JR, Knight JA and Bapat B: MLH1 -93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst 99: 463-474, 2007. (Pubitemid 47078735)
10. Yu JH, Bigler J, Whitton J, Potter JD and Ulrich CM: Mismatch repair polymorphisms and colorectal polyps: hMLH1-93G>A variant modifies risk associated with smoking. Am J Gastroenterol 101: 1313-1319, 2006.
11. Campbell PT, Curtin K, Ulrich CM, Samowitz WS, Bigler J, Velicer CM, Caan B, Potter JD and Slattery ML: Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 58: 661-667, 2009.
12. Allan JM, Shorto J, Adlard J, Bury J, Coggins R, George R, Katory M, Quirke P, Richman S, Scott D, Scott K, Seymour M, Travis LB, Worrillow LJ, Bishop DT and Cox A: MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer 123: 2456-2459, 2008.
13. Beiner ME, Rosen B, Fyles A, Harley I, Pal T, Siminovitch K, Zhang S, Sun P and Narod SA: Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev 15: 1636-1640, 2006.
14. Harley I, Rosen B, Risch HA, Siminovitch K, Beiner ME, McLaughlin J, Sun P and Narod SA: Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1. Gynecol Oncol 109: 384-387, 2008.
15. Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, Jang SS, Kim CH, Lee WK, Kam S, Park RW, Kim IS, Jung TH and Park JY: -93G->A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 112: 678-682, 2004.
16. Ito E, Yanagisawa Y, Iwahashi Y, Suzuki Y, Nagasaki H, Akiyama Y, Sugano S, Yuasa Y and Maruyama K: A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 256: 488-494, 1999.
17. Zhong X, Arita M, Koike J, Tsujita K and Hemmi H: A single nucleotide polymorphism in the promoter region of the hMLH1 gene: effect on transcriptional activity and application as a marker for detecting allelic loss. J Med Soc Toho Univ 48: 114-124, 2001.
18. Mei M, Liu D, Dong S, Ingvarsson S, Goodfellow PJ and Chen H: The MLH1 -93 promoter variant influences gene expression. Cancer Epidemiol 34: 93-95, 2010.
19. Evan G: Regulation of gene expression. Br Med Bull 47: 116-135, 1991.
20. Arita M, Zhong X, Min Z, Hemmi H and Shimatake H: Multiple sites required for expression in 5′-flanking region of the hMLH1 gene. Gene 306: 57-65, 2003.
21. Ianzano L, Zhao XC, Minassian BA and Scherer SW: Identification of a novel protein interacting with laforin, the EPM2a progressive myoclonus epilepsy gene product. Genomics 81: 579-587, 2003.
22. Wang Y, Liu Y, Wu C, Zhang H, Zheng X, Zheng Z, Geiger TL, Nuovo GJ, Liu Y and Zheng P: Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10: 179-190, 2006.
23. Chen H, Taylor NP, Sotamaa KM, Mutch DG, Powell MA, Schmidt AP, Feng S, Hampel HL, de la Chapelle A and Goodfellow PJ: Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 120: 1684-1688, 2007.
24. Samowitz WS, Curtin K, Wolff RK, Albertsen H, Sweeney C, Caan BJ, Ulrich CM, Potter JD and Slattery ML: The MLH1 -93 G